Research programme: cell permeable peptide fusion proteins - Portage Biotech

Drug Profile

Research programme: cell permeable peptide fusion proteins - Portage Biotech

Alternative Names: Cell permeable peptide platform technology - Portage Pharmaceuticals

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Portage Biotech
  • Class Conjugate-vaccines; Gene therapies; Nucleotides; Peptide vaccines; Recombinant fusion proteins
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye-Disorders; Neurological disorders

Most Recent Events

  • 26 Apr 2015 Portage Pharmaceuticals announces intention to submit IND for PPL 003
  • 14 Jul 2014 Cell permeable peptide fusion proteins from Portage Pharmaceuticals' pipeline are available for licensing after proof of concept trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top